Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience
Peptide receptor radionuclide therapy (PRRT) is a treatment option for well-differentiated, somatostatin receptor positive, unresectable or/and metastatic neuroendocrine tumors (NETs). Although high disease control rates seen with PRRT a significant number NET patients have a short progression-free...
Uložené v:
| Vydané v: | Frontiers in endocrinology (Lausanne) Ročník 14; s. 1270421 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Switzerland
Frontiers Media S.A
04.01.2024
|
| Predmet: | |
| ISSN: | 1664-2392, 1664-2392 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Peptide receptor radionuclide therapy (PRRT) is a treatment option for well-differentiated, somatostatin receptor positive, unresectable or/and metastatic neuroendocrine tumors (NETs). Although high disease control rates seen with PRRT a significant number NET patients have a short progression-free interval, and currently, there is a deficiency of effective biomarkers to pre-identify these patients. This study is aimed at determining the prognostic significance of biomarkers on survival of patients with NETs in initial PRRT treatment.
We retrospectively analyzed 51 patients with NETs treated with PRRT at the Department for nuclear medicine, University Clinical Center Kragujevac, Serbia, with a five-year follow-up. Eligible patients with confirmed inoperable NETs, were retrospectively evaluated hematological, blood-based inflammatory markers, biochemical markers and clinical characteristics on disease progression. In accordance with the progression og the disease, the patients were divided into two groups: progression group (n=18) and a non-progression group (n=33). Clinical data were compared between the two groups.
A total of 51 patients (Md=60, age 25-75 years) were treated with PRRT, of whom 29 (56.86%) demonstrated stable disease, 4 (7.84%) demonstrated a partial response, and 14 (27.46%) demonstrated progressive disease and death was recorded in 4 (7.84%) patients. The mean PFS was a 36.22 months (95% CI 30.14-42.29) and the mean OS was 44.68 months (95% CI 37.40-51.97). Univariate logistic regression analysis displayed that age (p<0.05), functional tumors (p<0.05), absolute neutrophil count (p<0.05), neutrophil-lymphocyte ratio-NLR (p<0.05), C-reactive protein-CRP (p<0.05), CRP/Albumin (p<0.05), alanine aminotransferase-ALT (p<0.05), were risk factors for disease progression. Multivariate logistic regression analysis exhibited that functional tumors (p<0.001), age (p<0.05), CRP (p<0.05), and ALT (p<0.05), were independent risk factors for the disease progression in patients with NETs. Tumor functionality was the most powerful prognostic factor. The median PFS (11.86 ± 1.41 vs. 43.38 ± 3.16 months; p=0.001) and OS (21.81 ± 2.70 vs 53.86 ± 3.70, p=0.001) were significantly shorter in patients with functional than non-functional NETs respectively.
The study's results suggest that tumor functionality, and certain biomarkers may serve as prognostic survival indicators for patients with NETs undergoing PRRT. The findings can potentially help to identify patients who are at higher risk of disease progression and tailor treatment strategies accordingly. |
|---|---|
| AbstractList | Peptide receptor radionuclide therapy (PRRT) is a treatment option for well-differentiated, somatostatin receptor positive, unresectable or/and metastatic neuroendocrine tumors (NETs). Although high disease control rates seen with PRRT a significant number NET patients have a short progression-free interval, and currently, there is a deficiency of effective biomarkers to pre-identify these patients. This study is aimed at determining the prognostic significance of biomarkers on survival of patients with NETs in initial PRRT treatment.
We retrospectively analyzed 51 patients with NETs treated with PRRT at the Department for nuclear medicine, University Clinical Center Kragujevac, Serbia, with a five-year follow-up. Eligible patients with confirmed inoperable NETs, were retrospectively evaluated hematological, blood-based inflammatory markers, biochemical markers and clinical characteristics on disease progression. In accordance with the progression og the disease, the patients were divided into two groups: progression group (n=18) and a non-progression group (n=33). Clinical data were compared between the two groups.
A total of 51 patients (Md=60, age 25-75 years) were treated with PRRT, of whom 29 (56.86%) demonstrated stable disease, 4 (7.84%) demonstrated a partial response, and 14 (27.46%) demonstrated progressive disease and death was recorded in 4 (7.84%) patients. The mean PFS was a 36.22 months (95% CI 30.14-42.29) and the mean OS was 44.68 months (95% CI 37.40-51.97). Univariate logistic regression analysis displayed that age (p<0.05), functional tumors (p<0.05), absolute neutrophil count (p<0.05), neutrophil-lymphocyte ratio-NLR (p<0.05), C-reactive protein-CRP (p<0.05), CRP/Albumin (p<0.05), alanine aminotransferase-ALT (p<0.05), were risk factors for disease progression. Multivariate logistic regression analysis exhibited that functional tumors (p<0.001), age (p<0.05), CRP (p<0.05), and ALT (p<0.05), were independent risk factors for the disease progression in patients with NETs. Tumor functionality was the most powerful prognostic factor. The median PFS (11.86 ± 1.41 vs. 43.38 ± 3.16 months; p=0.001) and OS (21.81 ± 2.70 vs 53.86 ± 3.70, p=0.001) were significantly shorter in patients with functional than non-functional NETs respectively.
The study's results suggest that tumor functionality, and certain biomarkers may serve as prognostic survival indicators for patients with NETs undergoing PRRT. The findings can potentially help to identify patients who are at higher risk of disease progression and tailor treatment strategies accordingly. Peptide receptor radionuclide therapy (PRRT) is a treatment option for well-differentiated, somatostatin receptor positive, unresectable or/and metastatic neuroendocrine tumors (NETs). Although high disease control rates seen with PRRT a significant number NET patients have a short progression-free interval, and currently, there is a deficiency of effective biomarkers to pre-identify these patients. This study is aimed at determining the prognostic significance of biomarkers on survival of patients with NETs in initial PRRT treatment.IntroductionPeptide receptor radionuclide therapy (PRRT) is a treatment option for well-differentiated, somatostatin receptor positive, unresectable or/and metastatic neuroendocrine tumors (NETs). Although high disease control rates seen with PRRT a significant number NET patients have a short progression-free interval, and currently, there is a deficiency of effective biomarkers to pre-identify these patients. This study is aimed at determining the prognostic significance of biomarkers on survival of patients with NETs in initial PRRT treatment.We retrospectively analyzed 51 patients with NETs treated with PRRT at the Department for nuclear medicine, University Clinical Center Kragujevac, Serbia, with a five-year follow-up. Eligible patients with confirmed inoperable NETs, were retrospectively evaluated hematological, blood-based inflammatory markers, biochemical markers and clinical characteristics on disease progression. In accordance with the progression og the disease, the patients were divided into two groups: progression group (n=18) and a non-progression group (n=33). Clinical data were compared between the two groups.MethodologyWe retrospectively analyzed 51 patients with NETs treated with PRRT at the Department for nuclear medicine, University Clinical Center Kragujevac, Serbia, with a five-year follow-up. Eligible patients with confirmed inoperable NETs, were retrospectively evaluated hematological, blood-based inflammatory markers, biochemical markers and clinical characteristics on disease progression. In accordance with the progression og the disease, the patients were divided into two groups: progression group (n=18) and a non-progression group (n=33). Clinical data were compared between the two groups.A total of 51 patients (Md=60, age 25-75 years) were treated with PRRT, of whom 29 (56.86%) demonstrated stable disease, 4 (7.84%) demonstrated a partial response, and 14 (27.46%) demonstrated progressive disease and death was recorded in 4 (7.84%) patients. The mean PFS was a 36.22 months (95% CI 30.14-42.29) and the mean OS was 44.68 months (95% CI 37.40-51.97). Univariate logistic regression analysis displayed that age (p<0.05), functional tumors (p<0.05), absolute neutrophil count (p<0.05), neutrophil-lymphocyte ratio-NLR (p<0.05), C-reactive protein-CRP (p<0.05), CRP/Albumin (p<0.05), alanine aminotransferase-ALT (p<0.05), were risk factors for disease progression. Multivariate logistic regression analysis exhibited that functional tumors (p<0.001), age (p<0.05), CRP (p<0.05), and ALT (p<0.05), were independent risk factors for the disease progression in patients with NETs. Tumor functionality was the most powerful prognostic factor. The median PFS (11.86 ± 1.41 vs. 43.38 ± 3.16 months; p=0.001) and OS (21.81 ± 2.70 vs 53.86 ± 3.70, p=0.001) were significantly shorter in patients with functional than non-functional NETs respectively.ResultsA total of 51 patients (Md=60, age 25-75 years) were treated with PRRT, of whom 29 (56.86%) demonstrated stable disease, 4 (7.84%) demonstrated a partial response, and 14 (27.46%) demonstrated progressive disease and death was recorded in 4 (7.84%) patients. The mean PFS was a 36.22 months (95% CI 30.14-42.29) and the mean OS was 44.68 months (95% CI 37.40-51.97). Univariate logistic regression analysis displayed that age (p<0.05), functional tumors (p<0.05), absolute neutrophil count (p<0.05), neutrophil-lymphocyte ratio-NLR (p<0.05), C-reactive protein-CRP (p<0.05), CRP/Albumin (p<0.05), alanine aminotransferase-ALT (p<0.05), were risk factors for disease progression. Multivariate logistic regression analysis exhibited that functional tumors (p<0.001), age (p<0.05), CRP (p<0.05), and ALT (p<0.05), were independent risk factors for the disease progression in patients with NETs. Tumor functionality was the most powerful prognostic factor. The median PFS (11.86 ± 1.41 vs. 43.38 ± 3.16 months; p=0.001) and OS (21.81 ± 2.70 vs 53.86 ± 3.70, p=0.001) were significantly shorter in patients with functional than non-functional NETs respectively.The study's results suggest that tumor functionality, and certain biomarkers may serve as prognostic survival indicators for patients with NETs undergoing PRRT. The findings can potentially help to identify patients who are at higher risk of disease progression and tailor treatment strategies accordingly.ConclusionThe study's results suggest that tumor functionality, and certain biomarkers may serve as prognostic survival indicators for patients with NETs undergoing PRRT. The findings can potentially help to identify patients who are at higher risk of disease progression and tailor treatment strategies accordingly. IntroductionPeptide receptor radionuclide therapy (PRRT) is a treatment option for well-differentiated, somatostatin receptor positive, unresectable or/and metastatic neuroendocrine tumors (NETs). Although high disease control rates seen with PRRT a significant number NET patients have a short progression-free interval, and currently, there is a deficiency of effective biomarkers to pre-identify these patients. This study is aimed at determining the prognostic significance of biomarkers on survival of patients with NETs in initial PRRT treatment.MethodologyWe retrospectively analyzed 51 patients with NETs treated with PRRT at the Department for nuclear medicine, University Clinical Center Kragujevac, Serbia, with a five-year follow-up. Eligible patients with confirmed inoperable NETs, were retrospectively evaluated hematological, blood-based inflammatory markers, biochemical markers and clinical characteristics on disease progression. In accordance with the progression og the disease, the patients were divided into two groups: progression group (n=18) and a non-progression group (n=33). Clinical data were compared between the two groups.ResultsA total of 51 patients (Md=60, age 25-75 years) were treated with PRRT, of whom 29 (56.86%) demonstrated stable disease, 4 (7.84%) demonstrated a partial response, and 14 (27.46%) demonstrated progressive disease and death was recorded in 4 (7.84%) patients. The mean PFS was a 36.22 months (95% CI 30.14-42.29) and the mean OS was 44.68 months (95% CI 37.40-51.97). Univariate logistic regression analysis displayed that age (p<0.05), functional tumors (p<0.05), absolute neutrophil count (p<0.05), neutrophil-lymphocyte ratio-NLR (p<0.05), C-reactive protein-CRP (p<0.05), CRP/Albumin (p<0.05), alanine aminotransferase-ALT (p<0.05), were risk factors for disease progression. Multivariate logistic regression analysis exhibited that functional tumors (p<0.001), age (p<0.05), CRP (p<0.05), and ALT (p<0.05), were independent risk factors for the disease progression in patients with NETs. Tumor functionality was the most powerful prognostic factor. The median PFS (11.86 ± 1.41 vs. 43.38 ± 3.16 months; p=0.001) and OS (21.81 ± 2.70 vs 53.86 ± 3.70, p=0.001) were significantly shorter in patients with functional than non-functional NETs respectively.ConclusionThe study’s results suggest that tumor functionality, and certain biomarkers may serve as prognostic survival indicators for patients with NETs undergoing PRRT. The findings can potentially help to identify patients who are at higher risk of disease progression and tailor treatment strategies accordingly. |
| Author | Djukic, Svetlana Sreckovic, Marijana Vukicevic, Verica Radojevic, Marija Zivkovic Djukic, Aleksandar Dagovic, Aleksandar Vukomanovic, Vladimir Simic Vukomanovic, Ivana Backovic, Milena Ignjatovic, Vesna Nedic, Katarina Vuleta Ignjatovic, Vladimir Milosavljevic, Neda Markovic, Marina Vuleta, Marko |
| AuthorAffiliation | 7 Department of Social Medicine, Faculty of Medical Sciences, University of Kragujevac , Kragujevac , Serbia 3 Department for Radiotherapy, University Clinical Center Kragujevac , Kragujevac , Serbia 4 Department for Medical Oncology, University Clinical Center Kragujevac , Kragujevac , Serbia 9 Clinic for Hematology, University Clinical Center Kragujevac , Kragujevac , Serbia 11 Department for Pathology, Faculty of Medicine, University of Belgrade , Belgrade , Serbia 12 Department for Cardiology, Clinical Hospital Center “Dr Dragisa Misovic Dedinje” , Belgrade , Serbia 8 Department of Health Promotion, Institute of Public Health , Kragujevac , Serbia 15 Emergency Medical Institute , Belgrade , Serbia 2 Department for Nuclear Medicine, University Clinical Center Kragujevac , Kragujevac , Serbia 13 Department of Pathophysiology, Faculty of Medical Sciences, University of Kragujevac , Kragujevac , Serbia 14 Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center Kragu |
| AuthorAffiliation_xml | – name: 15 Emergency Medical Institute , Belgrade , Serbia – name: 14 Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center Kragujevac , Kragujevac , Serbia – name: 2 Department for Nuclear Medicine, University Clinical Center Kragujevac , Kragujevac , Serbia – name: 4 Department for Medical Oncology, University Clinical Center Kragujevac , Kragujevac , Serbia – name: 6 Clinic for Cardiology, University Clinical Center Kragujevac , Kragujevac , Serbia – name: 7 Department of Social Medicine, Faculty of Medical Sciences, University of Kragujevac , Kragujevac , Serbia – name: 10 Department of Medical and Business-Technological, Academy of Professional Studies Sabac , Sabac , Serbia – name: 3 Department for Radiotherapy, University Clinical Center Kragujevac , Kragujevac , Serbia – name: 11 Department for Pathology, Faculty of Medicine, University of Belgrade , Belgrade , Serbia – name: 8 Department of Health Promotion, Institute of Public Health , Kragujevac , Serbia – name: 5 Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac , Kragujevac , Serbia – name: 12 Department for Cardiology, Clinical Hospital Center “Dr Dragisa Misovic Dedinje” , Belgrade , Serbia – name: 13 Department of Pathophysiology, Faculty of Medical Sciences, University of Kragujevac , Kragujevac , Serbia – name: 9 Clinic for Hematology, University Clinical Center Kragujevac , Kragujevac , Serbia – name: 1 Department of Nuclear Medicine and Clinical Oncology, Faculty of Medical Sciences, University of Kragujevac , Kragujevac , Serbia |
| Author_xml | – sequence: 1 givenname: Vladimir surname: Vukomanovic fullname: Vukomanovic, Vladimir – sequence: 2 givenname: Katarina Vuleta surname: Nedic fullname: Nedic, Katarina Vuleta – sequence: 3 givenname: Marija Zivkovic surname: Radojevic fullname: Radojevic, Marija Zivkovic – sequence: 4 givenname: Aleksandar surname: Dagovic fullname: Dagovic, Aleksandar – sequence: 5 givenname: Neda surname: Milosavljevic fullname: Milosavljevic, Neda – sequence: 6 givenname: Marina surname: Markovic fullname: Markovic, Marina – sequence: 7 givenname: Vladimir surname: Ignjatovic fullname: Ignjatovic, Vladimir – sequence: 8 givenname: Ivana surname: Simic Vukomanovic fullname: Simic Vukomanovic, Ivana – sequence: 9 givenname: Svetlana surname: Djukic fullname: Djukic, Svetlana – sequence: 10 givenname: Marijana surname: Sreckovic fullname: Sreckovic, Marijana – sequence: 11 givenname: Milena surname: Backovic fullname: Backovic, Milena – sequence: 12 givenname: Marko surname: Vuleta fullname: Vuleta, Marko – sequence: 13 givenname: Aleksandar surname: Djukic fullname: Djukic, Aleksandar – sequence: 14 givenname: Verica surname: Vukicevic fullname: Vukicevic, Verica – sequence: 15 givenname: Vesna surname: Ignjatovic fullname: Ignjatovic, Vesna |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38317712$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UstuEzEUHaEiWkp_gAXykk2CXzO22SBU8ahUCSRgbflxJ3E1sQePJyU_wTfjNClqWeCNr-49j8U5z5uTmCI0zUuCl4xJ9aaH6NOSYsqWhArMKXnSnJGu4wvKFD15MJ82F9N0g-vjmCglnzWnTDIiBKFnze-vGXxwJcQVKmtA05y3YWsGNOZkjQ1DKDuUetTPsYJSrJcIc057d5dDBFTmTcoTKhlMAY9uQ1mjEcYSPKAMrk4po2x8Jc9u2G-rTzbj7i36BtkGExH8GiEHiA5eNE97M0xwcfzPmx8fP3y__Ly4_vLp6vL99cLxTpWFEJz2LWNOKOU7ZoH2zHJqsO86wR0m3DMpeo9x74UUbYs7KVtPuKXeSkfYeXN10PXJ3Ogxh43JO51M0HeLlFfa5BLcANpJaVrnOHOYcSw72YkeW25Vb51y1lStdwetcbYb8A5iyWZ4JPr4EsNar9JWEyxrIqytCq-PCjn9nGEqehMmB8NgIqR50lRRqrgStKvQVw_N_rrcJ1oB8gBwOU1Thl67UMw-uuodhmqq9_3Rd_3R-_7oY38qlf5DvVf_D-kP8lXOGw |
| CitedBy_id | crossref_primary_10_1016_j_remn_2025_500138 crossref_primary_10_3390_ijms26178526 |
| Cites_doi | 10.12659/MSM.907182 10.31557/APJCP.2018.19.12.3597 10.1186/s13045-021-01187-y 10.21037/gs.2017.10.08 10.1001/jamanetworkopen.2021.24750 10.1016/j.canep.2019.101598 10.1016/j.esmoop.2021.100171 10.1245/s10434-018-6518-2 10.3389/fendo.2021.657698 10.1016/j.lanepe.2022.100510 10.3390/cancers13246290 10.22034/APJCP.2018.19.8.2177 10.1016/j.asjsur.2022.01.094 10.2967/jnumed.118.224386 10.1097/SLA.0000000000003162 10.1530/ERC-16-0538 10.21037/jtd.2017.09.82 10.1007/s00432-021-03672-w 10.3390/diagnostics11030504 10.1016/j.neo.2017.09.002 10.1016/S1470-2045(21)00572-6 10.1097/00000421-198212000-00014 10.3892/ol.2018.8413 10.1080/07435800.2020.1870234 10.1200/OP.21.00240 10.1089/cbr.2021.0053 10.3389/fendo.2022.861434 10.3390/biology10100950 10.1210/jc.2018-01214 10.1210/jc.2015-3114 10.2967/jnumed.119.236935 10.3389/fonc.2019.00906 10.1210/clinem/dgab588 10.3390/diagnostics12030737 10.3390/ijms24021418 |
| ContentType | Journal Article |
| Copyright | Copyright © 2024 Vukomanovic, Nedic, Radojevic, Dagovic, Milosavljevic, Markovic, Ignjatovic, Simic Vukomanovic, Djukic, Sreckovic, Backovic, Vuleta, Djukic, Vukicevic and Ignjatovic. Copyright © 2024 Vukomanovic, Nedic, Radojevic, Dagovic, Milosavljevic, Markovic, Ignjatovic, Simic Vukomanovic, Djukic, Sreckovic, Backovic, Vuleta, Djukic, Vukicevic and Ignjatovic 2024 Vukomanovic, Nedic, Radojevic, Dagovic, Milosavljevic, Markovic, Ignjatovic, Simic Vukomanovic, Djukic, Sreckovic, Backovic, Vuleta, Djukic, Vukicevic and Ignjatovic |
| Copyright_xml | – notice: Copyright © 2024 Vukomanovic, Nedic, Radojevic, Dagovic, Milosavljevic, Markovic, Ignjatovic, Simic Vukomanovic, Djukic, Sreckovic, Backovic, Vuleta, Djukic, Vukicevic and Ignjatovic. – notice: Copyright © 2024 Vukomanovic, Nedic, Radojevic, Dagovic, Milosavljevic, Markovic, Ignjatovic, Simic Vukomanovic, Djukic, Sreckovic, Backovic, Vuleta, Djukic, Vukicevic and Ignjatovic 2024 Vukomanovic, Nedic, Radojevic, Dagovic, Milosavljevic, Markovic, Ignjatovic, Simic Vukomanovic, Djukic, Sreckovic, Backovic, Vuleta, Djukic, Vukicevic and Ignjatovic |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3389/fendo.2023.1270421 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1664-2392 |
| ExternalDocumentID | oai_doaj_org_article_c88a5cc43c034086867f0b4b9fbc9cba PMC10840135 38317712 10_3389_fendo_2023_1270421 |
| Genre | Journal Article |
| GeographicLocations | Serbia |
| GeographicLocations_xml | – name: Serbia |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RPM ACXDI CGR CUY CVF ECM EIF IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c469t-7742f533c799d63be2f3b42a0d6674c014d387fd00fd7875506885d14b2db8c13 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 2 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001143669500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1664-2392 |
| IngestDate | Fri Oct 03 12:45:01 EDT 2025 Thu Aug 21 18:35:31 EDT 2025 Thu Sep 04 17:49:10 EDT 2025 Thu Apr 03 07:06:48 EDT 2025 Sat Nov 29 03:00:11 EST 2025 Tue Nov 18 21:25:43 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | overall survival PRRT functional tumors NET progression free survival |
| Language | English |
| License | Copyright © 2024 Vukomanovic, Nedic, Radojevic, Dagovic, Milosavljevic, Markovic, Ignjatovic, Simic Vukomanovic, Djukic, Sreckovic, Backovic, Vuleta, Djukic, Vukicevic and Ignjatovic. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c469t-7742f533c799d63be2f3b42a0d6674c014d387fd00fd7875506885d14b2db8c13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Aviral Singh, GenesisCare Australia Pty Ltd, Australia Reviewed by: Vineet Pant, Royal Liverpool University Hospital, United Kingdom These authors have contributed equally to this work and share first authorship Osborn Jiang, University of New South Wales, Australia Manoj Gupta, Rajiv Gandhi Cancer Institute and Research Centre, India |
| OpenAccessLink | https://doaj.org/article/c88a5cc43c034086867f0b4b9fbc9cba |
| PMID | 38317712 |
| PQID | 2922949726 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_c88a5cc43c034086867f0b4b9fbc9cba pubmedcentral_primary_oai_pubmedcentral_nih_gov_10840135 proquest_miscellaneous_2922949726 pubmed_primary_38317712 crossref_citationtrail_10_3389_fendo_2023_1270421 crossref_primary_10_3389_fendo_2023_1270421 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-04 |
| PublicationDateYYYYMMDD | 2024-01-04 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in endocrinology (Lausanne) |
| PublicationTitleAlternate | Front Endocrinol (Lausanne) |
| PublicationYear | 2024 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Zhou (B21) 2017; 23 Black (B24) 2019; 104 Gheorghișan-Gălățeanu (B12) 2023; 24 Wiese (B23) 2016; 101 Genç (B33) 2018; 25 Kalligeros (B28) 2021; 10 Zhu (B27) 2018; 19 Zhang (B2) 2022; 18 Shyr (B31) 2022; 45 Pauwels (B25) 2020; 61 Strosberg (B7) 2021; 22 Oronsky (B1) 2017; 19 Theiler (B18) 2021; 13 Xiong (B22) 2021; 14 Calissendorff (B35) 2021; 12 Sakin (B30) 2018; 19 Aalbersberg (B32) 2019; 60 Hayes (B6) 2021; 106 Puliani (B9) 2022; 13 Zandee (B34) 2017; 24 Ohlendorf (B8) 2021; 11 Oh (B10) 2022; 12 Wang (B16) 2019; 9 Chen (B26) 2018; 15 Xu (B3) 2021; 4 Satapathy (B11) 2022; 37 Swiha (B29) 2022; 148 Bodei (B4) 2017; 9 Severi (B5) 2021; 6 Oken (B14) 1982; 5 Solak (B20) 2021; 46 Vinault (B17) 2020; 272 Wyld (B19) 2019; 63 White (B15) 2022; 23 Öberg (B13) 2018; 7 |
| References_xml | – volume: 23 year: 2017 ident: B21 article-title: Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in surgically resectable pancreatic neuroendocrine tumors publication-title: Med Sci Monit doi: 10.12659/MSM.907182 – volume: 19 year: 2018 ident: B30 article-title: Factors affecting survival in neuroendocrine tumors: A 15-year single center experience publication-title: Asian Pac. J Cancer Prev doi: 10.31557/APJCP.2018.19.12.3597 – volume: 14 start-page: 173 year: 2021 ident: B22 article-title: Neutrophils in cancer carcinogenesis and metastasis publication-title: J Hematol Oncol doi: 10.1186/s13045-021-01187-y – volume: 7 year: 2018 ident: B13 article-title: Management of functional neuroendocrine tumors of the pancreas publication-title: Gland Surg doi: 10.21037/gs.2017.10.08 – volume: 4 year: 2021 ident: B3 article-title: Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2021.24750 – volume: 63 year: 2019 ident: B19 article-title: Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia publication-title: Cancer Epidemiol doi: 10.1016/j.canep.2019.101598 – volume: 6 year: 2021 ident: B5 article-title: Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials publication-title: ESMO Open doi: 10.1016/j.esmoop.2021.100171 – volume: 25 year: 2018 ident: B33 article-title: Recurrence of pancreatic neuroendocrine tumors and survival predicted by ki67 publication-title: Ann Surg Oncol doi: 10.1245/s10434-018-6518-2 – volume: 12 year: 2021 ident: B35 article-title: Characteristics, treatment, outcomes, and survival in neuroendocrine G1 and G2 pancreatic tumors: experiences from a single tertiary referral center publication-title: Front Endocrinol (Lausanne) doi: 10.3389/fendo.2021.657698 – volume: 23 year: 2022 ident: B15 article-title: Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study publication-title: Lancet Regional Health - Europe doi: 10.1016/j.lanepe.2022.100510 – volume: 13 start-page: 6290 year: 2021 ident: B18 article-title: Safety and efficacy of peptide-receptor radionuclide therapy in elderly neuroendocrine tumor patients publication-title: Cancers (Basel) doi: 10.3390/cancers13246290 – volume: 19 year: 2018 ident: B27 article-title: Impaired liver function implied shorter progression free survival for EGFR tyrosine kinase inhibitors publication-title: Asian Pac J Cancer Prev doi: 10.22034/APJCP.2018.19.8.2177 – volume: 45 year: 2022 ident: B31 article-title: Impact of tumor grade on pancreatic neuroendocrine tumors publication-title: Asian J Surg doi: 10.1016/j.asjsur.2022.01.094 – volume: 60 year: 2019 ident: B32 article-title: Parameters to predict progression-free and overall survival after peptide receptor radionuclide therapy: A multivariate analysis in 782 patients publication-title: J Nucl Med doi: 10.2967/jnumed.118.224386 – volume: 272 year: 2020 ident: B17 article-title: Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study(Groupe d’etude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne) publication-title: Ann Surger doi: 10.1097/SLA.0000000000003162 – volume: 24 year: 2017 ident: B34 article-title: Effect of hormone secretory syndromes on neuroendocrine tumor prognosis publication-title: Endocr Relat Cancer. doi: 10.1530/ERC-16-0538 – volume: 9 year: 2017 ident: B4 article-title: The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors publication-title: J Thorac Dis doi: 10.21037/jtd.2017.09.82 – volume: 148 year: 2022 ident: B29 article-title: Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS) publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-021-03672-w – volume: 11 year: 2021 ident: B8 article-title: Predictive and prognostic impact of blood-based inflammatory biomarkers in patients with gastroenteropancreatic neuroendocrine tumors commencing peptide receptor radionuclide therapy publication-title: Diagnostics (Basel) doi: 10.3390/diagnostics11030504 – volume: 19 start-page: 991 year: 2017 ident: B1 article-title: Nothing but NET: A review of neuroendocrine tumors and carcinomas publication-title: Neoplasia doi: 10.1016/j.neo.2017.09.002 – volume: 22 year: 2021 ident: B7 article-title: 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00572-6 – volume: 5 year: 1982 ident: B14 article-title: Toxicity and response criteria of the Eastern Cooperative Oncology Group publication-title: Am J Clin Oncol doi: 10.1097/00000421-198212000-00014 – volume: 15 year: 2018 ident: B26 article-title: Analysis of the clinicopathological features and prognostic factors of primary hepatic neuroendocrine tumors publication-title: Oncol Lett doi: 10.3892/ol.2018.8413 – volume: 46 year: 2021 ident: B20 article-title: Croatian ACC study group. Neutrophil-lymphocyte ratio as a prognostic marker in adrenocortical carcinoma publication-title: Endocr Res doi: 10.1080/07435800.2020.1870234 – volume: 18 year: 2022 ident: B2 article-title: Making sense of a complex disease: A practical approach to managing neuroendocrine tumors publication-title: JCO Oncol Pract doi: 10.1200/OP.21.00240 – volume: 37 year: 2022 ident: B11 article-title: Hematological markers as predictors of treatment outcomes with lutetium 177 (177Lu)-DOTATATE in patients with advanced neuroendocrine tumors publication-title: Cancer BiotherRadiopharm doi: 10.1089/cbr.2021.0053 – volume: 13 year: 2022 ident: B9 article-title: New insights in PRRT: lessons from 2021 publication-title: Front Endocrinol (Lausanne) doi: 10.3389/fendo.2022.861434 – volume: 10 year: 2021 ident: B28 article-title: Biomarkers in small intestine NETs and carcinoid heart disease: A comprehensive review publication-title: Biol (Basel) doi: 10.3390/biology10100950 – volume: 104 year: 2019 ident: B24 article-title: The inflammation-based index can predict response and improve patient selection in NETs treated with PRRT: A pilot study publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2018-01214 – volume: 101 year: 2016 ident: B23 article-title: C-reactive protein as a new prognostic factor for survival in patients with pancreatic neuroendocrine neoplasia publication-title: JCEM doi: 10.1210/jc.2015-3114 – volume: 61 year: 2020 ident: B25 article-title: Inflammation-based index and 68Ga-DOTATOC PET-derived uptake and volumetric parameters predict outcome in neuroendocrine tumor patients treated with 90Y-DOTATOC publication-title: J Nucl Med doi: 10.2967/jnumed.119.236935 – volume: 9 year: 2019 ident: B16 article-title: Consideration of age is necessary for increasing the accuracy of the AJCC TNM staging system of pancreatic neuroendocrine tumors publication-title: Front Oncol doi: 10.3389/fonc.2019.00906 – volume: 106 year: 2021 ident: B6 article-title: Metastatic medullary thyroid cancer: the role of 68Gallium-DOTA-somatostatin analogue PET/CT and peptide receptor radionuclide therapy publication-title: J Clin Endocrinol Metab doi: 10.1210/clinem/dgab588 – volume: 12 year: 2022 ident: B10 article-title: The predicting role of the neutrophil-to-lymphocyte ratio for the tumor grade and prognosis in pancreatic neuroendocrine tumors publication-title: Diagnostics (Basel). doi: 10.3390/diagnostics12030737 – volume: 24 year: 2023 ident: B12 article-title: The complex histopathological and immunohistochemical spectrum of neuroendocrine tumors-an overview of the latest classifications publication-title: Int J Mol Sci doi: 10.3390/ijms24021418 |
| SSID | ssj0000401998 |
| Score | 2.3359847 |
| Snippet | Peptide receptor radionuclide therapy (PRRT) is a treatment option for well-differentiated, somatostatin receptor positive, unresectable or/and metastatic... IntroductionPeptide receptor radionuclide therapy (PRRT) is a treatment option for well-differentiated, somatostatin receptor positive, unresectable or/and... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1270421 |
| SubjectTerms | Adult Aged Biomarkers Disease Progression Endocrinology functional tumors Humans Middle Aged NET Neuroendocrine Tumors - drug therapy Octreotide - therapeutic use overall survival progression free survival PRRT Radioisotopes - therapeutic use Receptors, Peptide - therapeutic use Retrospective Studies Serbia - epidemiology |
| Title | Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38317712 https://www.proquest.com/docview/2922949726 https://pubmed.ncbi.nlm.nih.gov/PMC10840135 https://doaj.org/article/c88a5cc43c034086867f0b4b9fbc9cba |
| Volume | 14 |
| WOSCitedRecordID | wos001143669500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1664-2392 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000401998 issn: 1664-2392 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-2392 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000401998 issn: 1664-2392 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQogL4k14VEbihpY6jhPb3AC14kCrHgDtzfJTVCpJld0g9cJP4DczY6erXYTgwiWyEluxPGN7vvH4G0JeKq6VahNIwKLrxlu5cE60i-C0DkxI2ebMc18-ypMTtVzq061UXxgTVuiBy8AdeKVs671oPGsE2N-qk4k54XRyXnuXTSOwerbAVF6DATYAkCi3ZACF6YMU-4CX_XjzGg9bBa93dqJM2P8nK_P3YMmt3efoDrk9m430benuXXIt9vfIzeP5YPw--Xk6YhljmCmYdHQ1wRIASkQxYUyh4r6kQ6K4jRXvH81MlthdjxcA6Xr6NowrmgPPY6Don6UXGPISIoVVEUrDSEcboPHkz_Ftubp1-YbCeoPM5TRuaJMfkM9Hh5_ef1jMqRYWHvDxGmxswRNYfl6CiLrGRZ4aJ7hloeuk8ICjQqNkCoylAFMcYE0HIg61cDw45evmIdnrhz4-JrRx3oVaO2UtE7X1ykZkCbQqATZjiVWkvhp242ceckyHcW4Aj6CoTBaVQVGZWVQVebVpc1FYOP5a-x1Kc1MTGbTzC9ArM-uV-ZdeVeTFlS4YmHF4jGL7OEwrwzXnWmjJu4o8Krqx-RXg_VrKmldE7WjNTl92v_RnXzOrd80UYt32yf_o_VNyC0ZEZF-ReEb21uMUn5Mb_vv6bDXuk-tyqfbzjIHn8Y_DXwx6IGQ |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predicting+the+survival+probability+of+functional+neuroendocrine+tumors+treated+with+peptide+receptor+radionuclide+therapy%3A+Serbian+experience&rft.jtitle=Frontiers+in+endocrinology+%28Lausanne%29&rft.au=Vukomanovic%2C+Vladimir&rft.au=Nedic%2C+Katarina+Vuleta&rft.au=Radojevic%2C+Marija+Zivkovic&rft.au=Dagovic%2C+Aleksandar&rft.date=2024-01-04&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-2392&rft.volume=14&rft_id=info:doi/10.3389%2Ffendo.2023.1270421&rft.externalDocID=PMC10840135 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-2392&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-2392&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-2392&client=summon |